Analyst consensus rating
Tempest Therapeutics Analyst Rating: none
TPST is rated none by 1 analysts with a $11.00 target. As of 2026-08-20.
Direct answer
Tempest Therapeutics's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $11.00.
Forecast evidence checked August 20, 2026.
Get free Tempest Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.01
- Average price target
- $11.00
- High price target
- $11.00
- Low price target
- $11.00
- Low target gap
- +989.1%
- Target upside
- +989.1%
- High target gap
- +989.1%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- August 20, 2026
- Valid through
- August 27, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Tempest Therapeutics?
Tempest Therapeutics has a verified none consensus. The same dataset has an average price target of $11.00.
How far are Tempest Therapeutics's low and high targets from the recorded price?
The low target implies +989.1%, while the high target implies +989.1%.
How many analysts are included in Tempest Therapeutics's consensus?
The verified consensus includes 1 analysts.
How is Tempest Therapeutics's target upside or downside calculated?
The average target of $11.00 is divided by the recorded price of $1.01, then one is subtracted to produce +989.1%. This does not guarantee a future return.
When was Tempest Therapeutics's analyst forecast verified?
The data was verified on 2026-08-20. The dataset is valid through 2026-08-27.